Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770091 · ClinicalTrials.gov registry record · Phase 3
Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis
A Phase 3 study, sponsored by John Fowler.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT03770091 is a Phase 3 study that has completed, run by John Fowler. The registered enrollment target is 40 participants.
The verdict
NCT03770091, a Phase 3 study, has completed, sponsored by John Fowler.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40, which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are both conservative and surgical with surgical options including osteotomy, bone excision, ligament reconstruction, and various prosthetic implants. The conservative treatment options, however, are limited to NSAIDs and bracing or steroid injections. Advances in topical therapies have the potential to deliver focused treatment to the CMC joint. Novel treatment of inflammation can potentially reduce inflammation and pain associated with progressing osteoarthritis. Theraworx Relief is an FDA registered foam that has theoretical impact on inflammation reduction in human subjects treated with the topical foam.
Interventions
- DRUG Placebo
- DRUG Theraworx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770091
The ClinicalTrials.gov registry entry for NCT03770091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Fowler, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03770091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03770091 about?
NCT03770091 is a clinical study titled "Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis". Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40, which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are both conservative and surgical with surgical options including osteotomy, bone excision, ligament reconstruction, a...
What is the current status of trial NCT03770091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2018-12-21. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT03770091?
The interventions under investigation include: Placebo (DRUG), Theraworx (DRUG).
Who is sponsoring clinical trial NCT03770091?
This trial is sponsored by John Fowler, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.